Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus

Therapies like topical steroids manage symptoms but there is currently no cure

- PMLiVE

Alzheimer’s disease – the future of diagnosis and treatment in Europe

Recognising symptoms early and acting quickly can make a real difference to the lives of patients

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

Skyhawk Therapeutics’ SKY-0515 shows positive results in Huntington’s disease

Huntington’s disease affects over 40,000 patients in the US and hundreds of thousands globally

- PMLiVE

Clinical trials on dementia: bridging access and innovation

Addressing the significant challenges surrounding the accessibility and availability of clinical trials

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

Genentech increases investment to $2bn for US manufacturing site

Roche and Genentech have a current commitment of $50bn for US manufacturing

- PMLiVE

Connecting through the chaos – why medical affairs needs creative problem-solving

By Ali Walsh

- PMLiVE

Genentech reports positive trial results for obesity treatment

The treatment is designed to tackle obesity by reducing appetite and regulating blood sugar

- PMLiVE

GC Therapeutics appoints Kate Haviland as Board Chair

Haviland was most recently President and CEO of Blueprint Medicines

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030

The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links